Shares in IMV Inc. (IMV) are spiking 134% in Tuesday’s pre-market trading after the clinical-stage biopharma company said it made “rapid progress” in developing its candidate vaccine to prevent COVID-19 infection.The stock surged to $4 in pre-market trading as IMV said that it was working closely with regulatory agencies and its partners to initiate clinical studies as quickly as possible. The plan for the Phase 1 clinical study, agreed with Health Canada, is a randomized controlled study, assessing the safety and immunogenicity of its vaccine candidate DPX-COVID-19, to be conducted in 84 healthy adults across two age cohorts.DPX-COVID-19, is based …read more
Source:: Yahoo Finance
